Browsing by Author "Craig, Timothy"

Now showing 1 - 4 of 4
  • Thumbnail Image
    ItemOpen Access
    Correction to: The International/Canadian Hereditary Angioedema Guideline
    (2020-05-06) Betschel, Stephen; Badiou, Jacquie; Binkley, Karen; Borici-Mazi, Rozita; Hébert, Jacques; Kanani, Amin; Keith, Paul; Lacuesta, Gina; Waserman, Susan; Yang, Bill; Aygören-Pürsün, Emel; Bernstein, Jonathan; Bork, Konrad; Caballero, Teresa; Cicardi, Marco; Craig, Timothy; Farkas, Henriette; Grumach, Anete; Katelaris, Connie; Longhurst, Hilary; Riedl, Marc; Zuraw, Bruce; Berger, Magdelena; Boursiquot, Jean-Nicolas; Boysen, Henrik; Castaldo, Anthony; Chapdelaine, Hugo; Connors, Lori; Fu, Lisa; Goodyear, Dawn; Haynes, Alison; Kamra, Palinder; Kim, Harold; Lang-Robertson, Kelly; Leith, Eric; McCusker, Christine; Moote, Bill; O’Keefe, Andrew; Othman, Ibraheem; Poon, Man-Chiu; Ritchie, Bruce; St-Pierre, Charles; Stark, Donald; Tsai, Ellie
    An amendment to this paper has been published and can be accessed via the original article.
  • Thumbnail Image
    ItemOpen Access
    International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
    (BioMed Central, 2010-07-28) Bowen, Tom; Cicardi, Marco; Farkas, Henriette; Bork, Konrad; Longhurst, Hilary J.; Zuraw, Bruce; Aygoeren-Pürsün, Emel; Craig, Timothy; Binkley, Karen; Hebert, Jacques; Ritchie, Bruce; Bouillet, Laurence; Betschel, Stephen; Cogar, Della; Dean, John; Devaraj, Ramachand; Hamed, Azza; Kamra, Palinder; Keith, Paul K.; Lacuesta, Gina; Leith, Eric; Lyons, Harriet; Mace, Sean; Mako, Barbara; Neurath, Doris; Poon, Man-Chiu; Rivard, Georges-Etienne; Schellenberg, Robert; Rowan, Dereth; Rowe, Anne; Stark, Donald; Sur, Smeeksha; Tsai, Ellie; Warrington, Richard; Waserman, Susan; Ameratunga, Rohan; Bernstein, Jonathan; Björkander, Janne; Brosz, Kristylea; Brosz,John; Bygum, Anette; Caballero, Teresa; Mike, Frank,; Fust, George; Harmat, George; Kanani, Amin; Kreuz, Wolfhart; Levi, Marcel; Li, Henry; Martinez-Saguer, Inmaculada; Moldovan, Dumitru; Nagy, Istvan; Nielsen, Erik W.; Nordenfelt, Patrik; Reshef, Avner; Rusicke, Eva; Smith-Foltz, Sarah; Späth, Peter; Varga, Lilian; Xiang, Zhi Yu
  • Thumbnail Image
    ItemOpen Access
    The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update
    (2018-02-27) Maurer, Marcus; Magerl, Markus; Ansotegui, Ignacio; Aygören-Pürsün, Emel; Betschel, Stephen; Bork, Konrad; Bowen, Tom; Boysen, Henrik B; Farkas, Henriette; Grumach, Anete S.; Hide, Michihiro; Katelaris, Constance; Lockey, Richard; Longhurst, Hilary; Lumry, William R.; Martinez-Saguer, Inmaculada; Moldovan, Dumitru; Nast, Alexander; Pawankar, Ruby; Potter, Paul; Riedl, Marc; Ritchie, Bruce; Rosenwasser, Lanny; Sánchez-Borges, Mario; Zhi, Yuxiang; Zuraw, Bruce; Craig, Timothy
    Abstract Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal.
  • Thumbnail Image
    ItemOpen Access
    The International/Canadian Hereditary Angioedema Guideline
    (2019-11-25) Betschel, Stephen; Badiou, Jacquie; Binkley, Karen; Borici-Mazi, Rozita; Hébert, Jacques; Kanani, Amin; Keith, Paul; Lacuesta, Gina; Waserman, Susan; Yang, Bill; Aygören-Pürsün, Emel; Bernstein, Jonathan; Bork, Konrad; Caballero, Teresa; Cicardi, Marco; Craig, Timothy; Farkas, Henriette; Grumach, Anete; Katelaris, Connie; Longhurst, Hilary; Riedl, Marc; Zuraw, Bruce; Berger, Magdelena; Boursiquot, Jean-Nicolas; Boysen, Henrik; Castaldo, Anthony; Chapdelaine, Hugo; Connors, Lori; Fu, Lisa; Goodyear, Dawn; Haynes, Alison; Kamra, Palinder; Kim, Harold; Lang-Robertson, Kelly; Leith, Eric; McCusker, Christine; Moote, Bill; O’Keefe, Andrew; Othman, Ibraheem; Poon, Man-Chiu; Ritchie, Bruce; St-Pierre, Charles; Stark, Donald; Tsai, Ellie
    Abstract This is an update to the 2014 Canadian Hereditary Angioedema Guideline with an expanded scope to include the management of hereditary angioedema (HAE) patients worldwide. It is a collaboration of Canadian and international HAE experts and patient groups led by the Canadian Hereditary Angioedema Network. The objective of this guideline is to provide evidence-based recommendations, using the GRADE system, for the management of patients with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. New to the 2019 version of this guideline are sections covering the diagnosis and recommended therapies for acute treatment in HAE patients with normal C1-INH, as well as sections on pregnant and paediatric patients, patient associations and an HAE registry. Hereditary angioedema results in random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased health-related quality of life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada, as in many countries, continues to be neither optimal nor uniform. It lags behind some other countries where there are more organized models for HAE management, and greater availability of additional licensed therapeutic options. It is anticipated that providing this guideline to caregivers, policy makers, patients, and advocates will not only optimize the management of HAE, but also promote the importance of individualized care. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency and intensive care physicians, primary care physicians, gastroenterologists, dentists, otolaryngologists, paediatricians, and gynaecologists who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.